New 'protector gene' switched off in two-thirds of ovarian cancers
A new gene that normally protects against ovarian cancer is switched-off in two-thirds of cases of the disease, reveals a study published in the journal Neoplasia today.
This ‘protector gene’, known as EPB41L3, is inactivated in 65 per cent of ovarian cancers.
And reactivating the gene halted tumour growth and triggered large numbers of the cancer cells to commit suicide.
The research, co-funded by Cancer Research UK and gynaecological cancer research charity The Eve Appeal, raises the prospect for developing therapies that mimic or restore the function of the gene to kill ovarian cancer cells in a targeted way.
Cancer Research UK’s Dr Simon Gayther, who led the study, said: “Previous studies have found similar ‘protector genes’ but ours is the first to uncover EPB41L3 as a gene specific to ovarian cancer.
“We also discovered that the gene is completely lost in about two-thirds of the ovarian tumours we looked at.
“When we switched it back on in these tumours, it had a positive effect in killing cancer cells. This is a very exciting result because it means therapies that mimic or reactivate this gene could be a way to beat many ovarian cancers.”
The scientists, based at UCL, used a cutting-edge approach which involves transferring whole chromosomes into ovarian cancer cells.
They found that introducing an additional copy of chromosome 18 boosted the activity of 14 key genes, triggering large numbers of the cells to die.
The scientists examined more than 800 ovarian tumours and found that one of the 14 genes – EPB41L3 – was inactivated in around two-thirds of malignant ovarian tumours, compared to less than a quarter of benign tumours and no normal ovarian cells.
Reactivating the gene had the same deadly effect on the cancer cells, suggesting that it was the trigger causing the cells to self-destruct.
Jane Lyons, CEO of The Eve Appeal, said “This research is an exciting step forward - a gene has been identified that can help halt the growth and spread of ovarian cancers. The challenge now is for the researchers and clinicians to find a way to use this new information to increase survival from the disease.”
Dr Lesley Walker, director of cancer information at Cancer Research UK, said: “We know that there is a class of genes that protect us from developing cancer. This is an exciting new one specific to ovarian cancer.
“Advanced ovarian cancer is very difficult to cure, which makes this type of research even more important.”
For media enquiries please contact the press office on 020 7061 8300 or, out-of-hours, the duty press officer on 07050 264 059.
- Dimitra Dafou et al. Microcell mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers (2010), Volume 12, Issue 7
Notes to Editor
Ovarian cancer is the fourth most common cancer in women, with 7,000 cases diagnosed in the UK each year.